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doi:10.1Objective: Clinical efficacy of cardiac cell therapy may be compromised by its target population, patients with
endothelial dysfunction. In vivo inhibition by endothelial dysfunction has been demonstrated for protein angio-
genesis but remains unclear for cell therapy. We examined whether hypercholesterolemia inhibits vasculogenic
effects of transplanted human circulating progenitor cells in ischemic tissue and whether L-arginine, a nitric oxide
donor, might prevent impairment.
Methods: Athymic rats were fed either normal (group A) or high-cholesterol diets, the latter without (group B) or
with (group C) oral L-arginine supplementation. Two weeks later, these rats underwent left femoral artery ligation
followed by injection of 2 3 106 human circulating progenitor cells into left hind-limb muscle. A fourth group
(group D) received supplemented high-cholesterol diets but no cells.
Results: Group B had biochemical evidence of endothelial dysfunction and reduced tissue endothelial nitric
oxide synthase expression, whereas group A levels were the same as in group C. By 21 postoperative days,
left hind-limb perfusion had recovered fully in groups A and C, partially in D, and not at all in B (38% lower
than group A, P  .004). Lower arteriolar densities were found in groups and B and D than in groups A and
C (P  .02). Engrafted human cell numbers were equivalent in all cell-transplanted groups after 3 weeks.
Conclusions: Endothelial dysfunction inhibited effects of cell therapy, specifically vasculogenesis, suggesting
a role for substrate modification to overcome this inhibition. Involved mechanisms appear related to use of cells
but not engraftment and require further investigation. (J Thorac Cardiovasc Surg 2010;139:209-216)Supplemental material is available online.Cardiac cell therapy encompasses all cell-based regenerative
approaches for refractory heart failure or intractable myocar-
dial ischemia. To date, this new modality has been investi-
gated by in vitro, in vivo, and phase I and II clinical trials
(Table E1).1,2 At this writing, however, cell therapy argu-
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Sof myocardial function in human beings, despite impressive
results in animal models.3,4
There are biologic issues that might explain the relative
lack of efficacy of cardiac cell therapy in human beings.
The recovery of injured or ischemic tissue may depend on
the active recruitment of regenerative cells, on the survival
of the cells, and on their phenotypes and functions within
the target tissue. Cell recruitment and retention are mediated
by the release of cytokines, such as stromal cell–derived
factor 1 or vascular endothelial growth factor, which are
upregulated by ischemia and depend on local nitric oxide
(NO) levels.5-7
In this context, it is relevant to consider that patients with
coronary artery disease, who constitute the majority of pa-
tients for whom cardiac cell therapy is intended, have abnor-
mal coronary endothelial function and decreased NO
bioavailability.7,8 Protein angiogenesis with fibroblast
growth factor 29 and vascular endothelial growth factor10
and also local endogenous angiogenesis7,11 depend on NO
bioavailability. In addition, a decreased in vivo therapeutic
effect of animal bone marrow cells (BMCs) on angiogenesis
in the presence of hypercholesterolemia and hypertension
has been reported, with an associated reduction in the NO
pathway.12,13 Recently, it was shown that transplanted cells
can quickly disappear from target tissue, and that it is therdiovascular Surgery c Volume 139, Number 1 209
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eNOS ¼ endothelial nitric oxide synthase
ET-1 ¼ endothelin 1
GM-CSF ¼ granulocyte macrophage–colony
stimulating factorIFN ¼ interferon
IL ¼ interleukin
NO ¼ nitric oxide
TNF ¼ tumor necrosis factorinduced humoral effects that play a crucial role in tissue re-
covery after cell therapy.14 The relationship between endo-
thelial dysfunction and transplanted cell engraftment, an
important consideration, has not previously been examined.
Furthermore, no study had yet investigated the effects of
hypercholesterolemia and endothelial dysfunction on trans-
planted human circulating progenitor cells (CPCs), which
constitute a more clinically relevant, specific, and possibly
potent vasculogenic cell population than BMCs of healthy
or pathologic animal origin.15,16
We report here for the first time that, in a rat model of
acute hind-limb ischemia treated with human CPCs, hyper-
cholesterolemia-induced endothelial dysfunction inhibited
vasculogenesis in response to human cell therapy and that
dietary supplementation with L-arginine, the substrate for
NO production,9 reversed this inhibition. We also demon-
strated that endothelial dysfunction had no effect on trans-
planted human cell engraftment after 3 weeks and that
other mechanisms are likely responsible for the inhibition
of vasculogenesis.
MATERIALS AND METHODS
Cell Isolation and Culture
Procurement methods were approved by the Human Research Ethics
Board of the University of Ottawa Heart Institute. After informed consent
was obtained, total peripheral blood mononuclear cells were isolated from
30-mL samples of fresh blood from healthy young donors by means of His-
topaque 1077 (Sigma, Oakville, Canada) density gradient centrifugation of
buffy coats and cultured to obtain CPCs as described previously.17
Animal Model
Procedures were performed with the approval of the University of
Ottawa Animal Care Committee and followed the guidelines of the Cana-
dian Council on Animal Care. All animals received humane care in compli-
ance with the Guide for the Care and Use of Laboratory Animals
(www.nap.edu/catalog/5140.html).
Athymic male Sprague–Dawley rats (250–300 g; Charles River Labora-
tories International, Inc, Wilmington, Mass) were divided into 3 dietary
groups: (1) rats in the control group (group A, n ¼ 12) were continuously
maintained on a standard diet; (2) rats in the high-cholesterol group (group
B, n¼ 12) were fed a 2% high-cholesterol diet; and (3) rats in the high-cho-rnal of Thoracic and Cardiovascular Surglesterol and L-arginine group (group C, n ¼ 12) were also fed a 2% high-
cholesterol diet. Two weeks after the initiation of this dietary modification,
the left proximal femoral artery of each rat was ligated and segmentally ex-
cised to induce hind-limb ischemia, as described previously.18 Shortly
thereafter, each rat received 2.0 3 106 40,6-diamidino-2-phenylindole–
labeled human CPCs in 200 mL phosphate-buffered saline solution, admin-
istered during the same surgical session by 10 equally distributed injections
into the ischemic thigh adductor muscle with a 27-gauge needle. As an ad-
ditional control, a second group of rats fed a high-cholesterol and L-arginine
diet underwent the same surgical procedure as described but did not receive
a cell injection (group D, n ¼ 6).
Immediately after surgery, rats in groups C and D were maintained on
the high-cholesterol diet and started on 2.25% L-arginine supplementation
in the drinking water, both of which were continued for the remainder of the
study. This L-arginine administration regimen was previously shown to
increase serum levels of L-arginine and tissue contents of stable NO metab-
olites in rats.7,19 In all rats, the right hind limb was not operated on and
served as a within-subject control. Rats were killed 21 days after the
operation, and their serum and bilateral hind-limb skeletal muscles were
collected. One animal died prematurely and was lost from group C
(n ¼ 11). Data for all procedures and analyses were collected from all
experimental animals (n ¼ 11–12 animals/group for all groups, except
for group D, where n ¼ 6).
Laser Doppler Blood Perfusion Analysis
The blood flow perfusion ratio of the ischemic (left) to the nonischemic
(right) hind limb was determined before and after femoral artery ligation as
well as on postoperative days 7, 14, and 21 by using a multifiber needle
probe containing 8 separate collecting fibers and a laser Doppler blood
flow monitor (Moor Instruments Ltd, Axminster, UK). To this end, rats
were anesthetized with isoflurane, and the hind limbs were shaved and
cleaned. The probe was calibrated with a physical standard according to
the manufacturer protocol. The probe was then placed on the skin over
the main rat hind-limb adductor muscle and, after the flux readings were al-
lowed to stabilize for 2 to 3 minutes, a 30-second recording was taken with
data-acquisition software (moorLAB V1.3; Moor Instruments). Readings
were made for both limbs, and the average flux from the 8 separate probes
during the 30-second recording was used to calculate flux ratio.
Serum Biochemical Analyses
Serum samples (approximately 230 mL) were analyzed for circulating
levels of endothelin 1 (ET-1) and big ET-1 (bET-1) according to the proce-
dure reported by Kumarathasan and associates.20 Briefly, serum samples
stabilized with 3,4-dichloroisocoumarin (Sigma) were deproteinized with
acidified acetone and clarified by molecular weight cutoff filtration (30
kDa). Samples were reconstituted with phosphate-buffered saline solution
(Sigma) and endothelins were separated with a Gilson high-performance
liquid chromatograph (Mandel Scientific Company Inc, Guelph, Ontario,
Canada) on a LC-318 Zorbax column (Agilent Technologies, Inc, Santa
Clara, Calif) by gradient elution with a water/acetonitrile mobile phase, fol-
lowed by fluorescence detection at an excitation wavelength of 280 nmwith
an emission wavelength of 340 nm. Endothelin calibration standards ET-1
(Sigma) and bET-1 (Bachem California, Inc, Torrance, Calif) were used.
Ratios of ET-1 to nitrite and ET-1 to bET-1 were calculated.
Nitrite analysis was also conducted according to a previously reported
procedure.20 Briefly, serum samples (50 mL) treated with ethylenediamine-
tetraacetic acid and diethylenetriaminepentaacetic acid (Sigma) were ther-
molyzed at 86C, cooled, and filtered through 10-kDa molecular weight
cutoff filters. The samples were treated with nitrate reductase (Sigma) at
room temperature for 1 hour and were broken into derivatives with 2,3 dia-
minonaphthalene (Molecular Probes, Eugene, Ore). Fluorescence measure-
ments were made at an excitation wavelength of 360 nm and an emission
wavelength of 460 nm on a Cytofluor 2350 multiplate fluorescence detector
(Millipore, Bedford, Mass).ery c January 2010
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and butylated hydroxytoluene (to prevent autoxidation) were analyzed for
3-nitrotyrosine with a previously reported high-performance liquid chroma-
tography CoulArray method.21 In summary, stabilized serum samples were
deproteinized with acidified acetone and clarified by molecular weight cut-
off filtration (30 kDa). Samples were reconstituted with acidified deionized
water, and the 3-nitrotyrosine peak was separated with high-performance
liquid chromatography (ESA, Chelmsford, Mass) on a LC-18 Zorbax col-
umn (Agilent Technologies) by isocratic elution with a citrate/acetate buffer
as mobile phase, followed by coulometric array detection at 600 mV with
the CoulArray detector (ESA). The calibration standard for 3-nitrotyrosine
was obtained from Sigma.
The cytokines interleukin (IL) 1a, IL-1b, IL-2, IL-4, IL-6, interferon g
(IFN-g), tumor necrosis factor a (TNF-a), IL-10, and granulocyte macro-
phage-colony stimulating factor (GM-CSF) in plasma were analyzed with
a Bioplex liquid antibody array (Bio-Rad Laboratories, Hercules, Calif) ac-
cording to manufacturer protocol. All treatment groups had the plasma level
for each cytokine normalized to the mean level calculated for group A. An
inflammatory index22 was calculated from the ratio of the average changes
of proinflammatory cytokines IL-1a, IL-1b, IL-2, IL-4, IL-6, IFN-g, and
TNF-a to the average changes of anti-inflammatory cytokines IL-10 and
GM-CSF, as follows: Inflammatory index ¼ (DTNF-aþDIFN-gþDIL-
1aþDIL-1bþDIL-2þDIL-4þDIL-6)/(DGM-CSFþDIL-10), whereD rep-
resents the average change in concentration.
Histologic Assessment
Animals were killed on postoperative day 21 with an overdose of isoflur-
ane gas and an intracardiac injection of potassium chloride. Ischemic (left)
and nonischemic (right) hind-limb main thigh adductor muscles were har-
vested, fixed with 4% paraformaldehyde, stored in 10% neutral buffered
formalin, serially sectioned, and embedded in paraffin. Slides were prepared
from 4-mm serial sections at different levels. Sections were stained with he-
matoxylin–phloxine–saffron and Masson trichrome staining.
Immunohistochemical localization of endothelial nitric oxide synthase
(eNOS) was performed with the use of anti-eNOS antibody (1:100; Abcam
plc, Cambridge, Mass), with subsequent development in the DAKOLSAB2
system followed by diaminobenzidine (DAKO Corporation, Carpenteria,
Calif), as described previously.23 The level of eNOS expression was calcu-
lated as the percentage of the area in sections staining positive for eNOS. As
an endothelial cell marker, CD31 was localized in transplanted cells by im-
munohistochemical staining with anti-CD31 (1:50; Millipore Bioscience
Research Reagents, Temecula, Calif) according to manufacturer’s protocol.
The extent of vascularization was assessed by measuring arteriolar den-
sity in light microscopic sections stained with hematoxylin–phloxine–saf-
fron and was calculated as the number of arterioles per square millimeter.
Arteriolar density was further confirmed by direct staining with an a-smooth
muscle actin antibody (1:400; Millipore Bioscience Research Reagents)
with visualization by fluorescence microscopy. An index of vascularity
was also calculated, consisting of the ratio between arteriolar counts in
the ischemic and nonischemic limbs. Capillary density was also assessedFIGURE 1. Immunohistochemical analysis of tissue endothelial nitric oxide syn
levels in ischemic muscle of rats in groups A (A), B, (B), and C (C). Scale bar
The Journal of Thoracic and Caby determining the ratio of the number of capillaries (stained CD31þ) to
that of muscle fibers. Arteriolar and capillary densities were determined
from 6 random microscopic fields (at a minimum of 3 tissue levels) from
each animal by an observer blinded to group.
Fluorescent in Situ Hybridization
Xenogeneic transplant allowed the use of the fluorescent in situ
hybridization technique to detect specifically donor-derived cells by using
a Cy3-labeled pancentromeric human chromosome probe (Cambio Ltd,
Cambridge, UK) according to the manufacturer protocol. Briefly, sections
were dewaxed, rehydrated, incubated in sodium thiocyanate, and then
treated with pepsin. The reaction was quenched with 0.2% glycine, and sec-
tions were postfixed in 4% paraformaldehyde, dehydrated and air-dried.
The pancentromeric chromosome paint was applied to the slide, sealed
with a glass coverslip, heated to 80C for 10 minutes, and incubated over-
night at 37C. The slides were then washed successively with formamide,
standard saline citrate solution, and 10% polysorbate 20 in standard saline
citrate solution, all provided by the manufacturer. Slides were then treated
with mounting medium containing 40,6-diamidino-2-phenylindole. Slides
were examined with fluorescence microscopy where the nuclei of the trans-
planted human cells in combination with the 40,6-diamidino-2-phenylindole
stained purple. The number of positive cells was determined from 6 random
microscopic high-power fields in a blinded fashion.
Statistical Analysis
Data are expressed as mean SEM. Statistical analyses were performed
in Intercooled Stata 9.2 (Stata, College Station, Tex). Comparisons of con-
tinuous data between groups were performed with a 1-way analysis of var-
iance or a 2-tailed Student t test, both with Bonferroni correction for
repeated measures as appropriate. Doppler data were analyzed with a linear
regression model that used the number of days after the procedure and the
response group as the independent variables and the standardized Doppler
signal as the dependent variable.
RESULTS
Tissue eNOS Expression
Expression of eNOS (as a percentage of total tissue area)
in the ischemic hind limb was significantly reduced in group
B (0.79% 0.09%) relative to groups A (1.91% 0.23%,
P< .001) and C (1.62%  0.16%, P ¼ .006; Figure 1).
L-Arginine treatment restored hind-limb tissue eNOS in
rats fed a hypercholesterolemic diet to a level equivalent to
that observed in the control group (P ¼ .73).
Circulating Endothelins and Nitrites
The ratio of ET-1 to nitrite in group A was 3.6% 0.4%,
and the high-cholesterol diet significantly increased thisthase expression. Representative images of endothelial nitric oxide synthase
represents 150mm.
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FIGURE 2. Biochemical analysis of endothelial function. Ratio of endothelin 1 (ET1) to nitrite (A), ratio of endothelin 1 (ET1) to big endothelin 1 (bET1)
(B), and nitrotyrosine level (C) were all significantly increased in serum of group B (CHOL) relative to groups A (NORM) and C (CHOL-ARG). Asterisk
indicates P< .05 versus other groups.
FIGURE 3. Inflammatory index. Ratio of proinflammatory to anti-inflam-
matory cytokine expression was greater in group B (CHOL) than in groups
A (NORM) and C (CHOL-ARG).
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ginine supplementation in group C restored the ratio (4.2 
0.7%) to control level (P>.999). The ratio of ET-1 to bET-1
was also examined (Figure 2, B). There was a trend for the
ratio of circulating ET-1 to bET-1 in groups A (54% 
10%) and C (59%  11%) to be lower than that in group
B (88%  17%, P ¼ .08 and P ¼ .11 for B vs A and B
vs C, respectively).
Serum Nitrotyrosine Levels
Serum nitrotyrosine levels were significantly higher in
group B (950  226 pmol/mL) than in groups A (371 
119 pmol/mL) and C (391  86 pmol/mL, P< .04).
Inflammatory Index
The inflammatory index, calculated from the ratio be-
tween proinflammatory and anti-inflammatory cytokine
levels, was elevated in group B (2.40  0.70) relative to
group A (1.25  0.25, P ¼ .15). Treatment with L-arginine
restored the index to a level equivalent to that in group A
(group C 1.30  0.32, P ¼ .9; Figure 3). Examination of in-
dividual cytokine levels revealed a trend toward decreased
expression of several proinflammatory cytokines with L-ar-
ginine treatment (group C) relative to group B (Table E2).
Vascularization
Arteriolar density was reduced in group B relative to
values in groups A and C (Figure 4, A–C). The number of
arterioles in group B (6.8  0.6 arterioles/mm2) was signif-212 The Journal of Thoracic and Cardiovascular Surgicantly reduced relative to the numbers in groups A (8.7 
0.8 arterioles/mm2) and C (8.8  0.7 arterioles/mm2, P<
.04; Figure 4, D). When comparing groups according to
the ratio of ischemic (left) to nonischemic (right) hind-
limb arteriolar count, the same result was observed; that is,
the arteriolar count ratio in group B (0.81  0.10) was sig-
nificantly less than that in groups A (1.23  0.15) and C
(1.31 0.16, P<.01; Figure 4, E). The number of arterioles
and the arteriolar count ratio (ischemic/nonischemic hind
limb) in group D (6.2  0.5 arterioles/mm2 and 0.74 
0.10, respectively) were significantly reduced relative to
groups A and C (P< .05).ery c January 2010
FIGURE 4. Arteriolar density. Representative images of a-smooth muscle actin–stained arterioles in ischemic muscle of rats in groups A (A, NORM), B (B,
CHOL), and C (C, CHOL-ARG). Both arteriolar density (D) and ratio of ischemic to nonischemic arteriolar count (E) were significantly reduced in group B
relative to groups A and C. Scale bar represents 250 mm. Asterisk indicates P<.04 versus other groups; double asterisk indicates P<.01 versus other groups.
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per muscle fiber, was also significantly reduced in group B
(0.96  0.06) relative to groups A and C (1.44  0.10 and
1.59  0.13, respectively, P< .02; Figure 5).
Hind-Limb Perfusion
Laser Doppler analysis (Figure 6) revealed that the im-
paired blood flow (measured as ischemic/nonischemic
flow ratio) after left femoral ligation was restored in group
A after 3 weeks (0.97  0.06) but did not recover in group
B (0.59  0.03). This represents a flow reduction of 38%
in group B relative to group A (P< .001). Rats fed the
high-cholesterol diet but receiving L-arginine (group C)
had restoration of hind-limb blood flow that was signifi-
cantly improved at 14 and 21 days (0.86  0.03 and 0.98
 0.04, respectively) relative to group B (0.64  0.03 and
0.60  0.03 at 14 and 21 days, respectively, P< .001).
Hind-limb perfusion in group D with time (0.74  0.1 and
0.86  0.04 at 14 and 21 days, respectively) was signifi-
cantly lower than in groups A and C (P ¼ .004) and greater
than in group B (P ¼ .02).
Human Cell Engraftment
The number of transplanted human cells (as determined
by in situ hybridization with the human-specific pancentro-
meric probe) within the ischemic hind limb at 3 weeks after
injection was not different among treatment groups (Fig-
ure 7). Specifically, there were average numbers of 0.43 
0.12, 0.38  0.11 and 0.38  0.11 positive transplanted hu-
man cells/field of view for groups A, B, and C, respectively
(P ¼ .9).The Journal of Thoracic and CaDISCUSSION
In this study, the effects of hypercholesterolemia-induced
endothelial dysfunction on the efficacy of human cell ther-
apy to improve revascularization of ischemic tissue in im-
munocompromised rats were examined. The main findings
were as follows: (1) Hypercholesterolemia-induced endo-
thelial dysfunction had an adverse effect on the vasculogenic
response to human progenitor cell therapy. (2) Endothelial
dysfunction did not affect the number of engrafted donor
human cells in the subacute period; that is, at 3 weeks after
injection. (3) The NO donor L-arginine rescued animals from
the hypercholesterolemia-induced endothelial dysfunction
and its associated oxidative stress and inflammatory state.
(4) Finally, L-arginine supplementation prevented the hyper-
cholesterolemia-induced impairment in human cell–based
vasculogenesis. This study demonstrates that rescue from
endothelial dysfunction restores the host response to human
cell–based vasculogenic therapy in vivo, suggests a role for
the cells themselves, and implies that mechanisms other than
engraftment and differentiation of the transplanted cells are
involved.
Previous work has established the in vivo inhibitory
effects of endothelial dysfunction on the effectiveness of
protein-based angiogenesis.9,10 A few studies have also
suggested that cell-based vasculogenesis could be affected
by endothelial dysfunction. For example, Aicher and
colleagues5 demonstrated that eNOS deficiency resulted in
defective mobilization of stem and progenitor cells, which
contributed to impairment of endogenous ischemia-induced
neovascularization. This finding indicates that NO, the avail-
ability of which is altered in endothelial dysfunction, hasrdiovascular Surgery c Volume 139, Number 1 213
FIGURE 5. Capillary density. Representative images of CD31-stained capillaries (arrowheads) in ischemic muscle of rats in groups A (A, NORM), B (B,
CHOL), and C (C, CHOL-ARG). D, Capillary density was significantly reduced in group B relative to groups A and C. Scale bar represents 75 mm. Asterisk
indicates P< .02 versus other groups.
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neous collateral formation. Similarly, deNigris and associ-
ates12,13 transplanted BMCs into ischemic hind limbs of
hypercholesterolemic and hypertensive mice and observedFIGURE 6. Hind-limb perfusion. Laser Doppler analysis was used to mea-
sure perfusion before (Pre-op) and after (Post-op) operation and at 7, 14,
and 21 postoperative days. Data are presented as average ratio of ischemic
to nonischemic limb blood flow. Asterisk indicates P<.001 between groups
B (CHOL) and C (CHOL-ARG). NORM, Group A.
214 The Journal of Thoracic and Cardiovascular Surgan enhanced angiogenic response when cells were delivered
in combination with metabolic intervention, with an associ-
ated increase in NO bioavailability. The BMCs used in these
studies were isolated from the pathologically affected ani-
mals, in contrast to the clinically relevant human source
used in our experiments.
In our study, we directly confirmed in an animal model
with CPCs from healthy human donors that endothelial
dysfunction as a substrate negatively influenced the in
vivo response to cell therapy. Similarly, autologous stem
or progenitor cells derived from patients with cardiovascular
disease may have defects in their regenerative activities,24,25
andmodification of the transplanted cell might be a prerequi-
site for efficacy in cell therapy. We showed that manipulat-
ing the host environment, which includes addressing the role
of endothelial dysfunction as investigated by our group, will
likely be required to improve the regenerative potential of
cell therapy, independently of whether the transplanted
cell has compromised function or is fully healthy. In this
study, despite the use of cells with preserved functional ac-
tivity,15,16 the mechanism did not relate to the number of en-
grafted transplanted cells at 3 weeks.
Recent studies have raised questions regarding engraft-
ment and transdifferentiation of transplanted cells, and theery c January 2010
FIGURE 7. Cell engraftment at 3 weeks after cell transplant. A, Represen-
tative image of transplanted human circulating progenitor cell (arrowhead),
stained with human-specific pancentromeric probe (purple nuclei), found
engrafted in ischemic hind-limb muscle of rat 3 weeks after injection. All
cell nuclei are stained with 40,6-diamidino-2-phenylindole (blue). Inset
shows higher magnification of stained human cell. Scale bar represents
75 mm. B, Number of transplanted human cells found engrafted in ischemic
hind limb after 2 weeks was not different (P ¼ .9) between groups A
(NORM), B (CHOL), and C (CHOL-ARG).
Suuronen et al Evolving Technology/Basic Science
E
T
/B
Spremise that these are the primary mechanisms responsible
for therapeutic effects is being challenged.14,26 Rather, it is
believed that neovascularization of the dysfunctional myo-
cardium from paracrine or humoral factors and secondary
recruitment of host stem or progenitor cells are the likely
mechanisms leading to functional improvement.14,16,26 Re-
cently, Cho and colleagues14 demonstrated that transplanted
cells can quickly disappear from the target tissue and that it is
the induced humoral effects, which are sustained by the host
tissues, that play a crucial role in tissue recovery after cell
therapy. If humoral effects sustained by the host stand as
the main mechanism for the therapeutic benefit of cell trans-
plant, it is therefore reasonable to expect that endothelial
dysfunction will minimize or abolish the effects of cell ther-
apy. In this study, the level of human cell engraftment at 3
weeks was not affected by endothelial dysfunction, suggest-The Journal of Thoracic and Caing that mechanisms other than engraftment and differentia-
tion, such as host-sustained humoral effects, may have been
responsible for the observed inhibitory effects. This notion is
further corroborated by the observation that animals fed
a high-cholesterol diet with L-arginine supplementation but
no cell transplant (group D) demonstrated only partial resto-
ration of perfusion. This suggests that L-arginine treatment
improves an endogenous angiogenic response, as has been
previously reported27 and that cell transplant may augment
this endogenous response, possibly through the interaction
of host and transplanted cells and the associated humoral ef-
fects. The exact mechanisms by which transplanted cells
confer their benefits in this context remain incompletely un-
derstood, and this is an area for future, more targeted, inves-
tigation.
One limitation of the study is that tissues were examined
after 3 weeks, and therefore the possibility that early engraft-
ment, allogenic immune response, and differentiation may
have differed between the groups and resulted in the ob-
served effects cannot be excluded. Nevertheless, minimal al-
logenic response is typically observed with the use of an
athymic rat model, according to our data and previous stud-
ies,18,28 and this would be anticipated to be equivalent in the
3 treatment groups because all received equal numbers of
transplanted human cells. Additionally, the persistences of
the observed effects were not examined beyond 3 weeks,
and the long-term benefits of substrate modification to re-
verse the inhibitory action of endothelial dysfunction on
cell therapy constitutes a focus of future study. Notwith-
standing these caveats, it remains to be elucidated whether
an improvement in cell retention, from the use of delivery
matrices for instance,18 might augment the host response
to human cell therapy in the context of endothelial dys-
function.
Several parameters helped establish that the hypercholes-
terolemic animals used in this study had endothelial dys-
function. First, ET-1 is an important player in the
development of vascular dysfunction.29 The ratio of ET-1
to nitrite constitutes an index of vasoconstriction and indi-
cates a mismatch between endothelin expression and the
eNOS pathway; this ratio was increased in group B. Second,
bET-1 is the precursor to formation of ET-1, and the high
ratio of ET-1 to bET-1 observed in group B indicates either
reduced de novo synthesis of bET-1 or increased conversion
of bET-1 to the ET-1 peptide relative to the control group.
Third, the level of the peroxynitrite marker nitrotyrosine,
an indicator of oxidative stress and also of vascular func-
tion,30 was elevated in group B relative to the normal control
group. Finally, eNOS level in the ischemic hind-limb tissue
was reduced in group B relative to the control group and was
restored by L-arginine supplementation. Overall, the ratio of
serum ET-1 to nitrite ratio, the ratio of serum ET-1 to bET-1,
the nitrotyrosine level, and the eNOS level indicate the
presence of endothelial dysfunction in the animals fedrdiovascular Surgery c Volume 139, Number 1 215
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Sa high-cholesterol diet, which was rescued by the NO donor
L-arginine with respect to each parameter. In addition,
examination of the ratio between proinflammatory and
anti-inflammatory cytokines present in the serum suggests
a proinflammatory state in the group B rats, which again
was improved by supplementation with L-arginine.
This study indicates that endothelial dysfunction inhibits
vasculogenic cell therapy in vivo with healthy functional hu-
man cells, which provide an effect but not through a subacute
transplanted cell engraftment mechanism, and suggests
a role for substrate modification to improve the results of
therapy. Improving our understanding of the role of endothe-
lial dysfunction in the host responses to ischemia and to cell
treatment may expedite progress toward development of
more effective cell-based vasculogenic and possibly myo-
genic therapies in human beings.
We thank Suzanne Crowe, Alain Filiatreault, and Erica Blais for
their technical assistance.References
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TABLE E1. Completed trials that have used bone marrow mononuclear cells or EPCs after myocardial infarction (partial list)
Study No.* Cell type Delivery Time after MI (d) Outcome
Nonrandomized (primarily safety)
Strauer et alE1 10 BM-MNCs IC 8  2 Stroke volume [; infarct size Y; wall motion [; perfusion [
TOPCARE-AMIE2,E3 59 BM-MNCs, PB-EPCs IC 4.9  1.5 LVEF [; remodeling Y; infarct size Y; perfusion [
Fernandez-Aviles et alE4 20 BM-MNCs IC 13.5  5.5 LVEF [; wall motion [; ESV Y
Bartunek et al5 19 CD133þBM-MNCs IC 11.6  1.4 LVEF [; perfusion [; myocardial viability [
Randomized
Ge et alE6 10 BM-MNCs IC <1 LVEF [; perfusion [
Li et alE7 35 PB-EPCs IC 7  5 LVEF [; wall motion [
BOOSTE8,9 30 BM-MNCs IC 4.8  1.3 LVEF [ (6 mo only)
Janssens et alE10 33 BM-MNCs IC <1 No increase in LVEF; infarct size [; regional systolic function [
REPAIR-AMIE11,E12 102 BM-MNCs IC 4.3  1.3 LVEF [; greater benefit in<49% LVEF and>5 d after MI
ASTAMIE13 50 BM-MNCs IC 6.0  1.3 No benefit
MI, Myocardial infarction; BM-MNC, bone marrow mononuclear cell; IC, intracoronary; PB-EPC, peripheral blood-endothelial progenitor cells; LVEF, left ventricular ejection
fraction; ESV, end-systolic volume. *Number of patients receiving cells.
TABLE E2. Levels of circulating proinflammatory and anti-
inflammatory cytokines
Control HCD
HCD with
arginine P value*
Proinflammatory cytokines
IL-1a 1.00  0.22 0.60  0.18 0.39  0.11 .06
IL-1b 1.00  0.15 0.97  0.21 0.63  0.09 .17
IL-2 1.00  0.68 0.28  0.20 0.68  0.52 .6
IL-4 1.00  0.58 1.70  1.13 0.77  0.48 .67
IL-6 1.00  0.21 0.32  0.15 0.07  0.04 <.001
IFN-g 1.00  0.26 0.52  0.23 0.37  0.19 .16
TNF-a 1.00  0.15 0.83  0.15 0.85  0.21 .78
Anti-inflammatory cytokines
IL-10 1.00  0.45 0.70  0.20 0.61  0.05 .54
GM-CSF 1.00  0.29 0.40  0.24 0.31  0.11 .08
P/A ratio 1.25  0.25 2.40  0.70 1.30  0.32 .16
Levels of individual cytokines are mean  SEM, obtained from serum 3 weeks after
cell transplant into ischemic hind-limb muscle and normalized to mean level of control
(normal diet) group.HCD,High-cholesterol diet; IL, interleukin; IFN, interferon; TNF,
tumor necrosis factor; GM-CSF, granulocyte-macrophage colony-stimulating factor;
P/A ratio, ratio of proinflammatory to anti-inflammatory cytokines. *P values calcu-
lated with 1-way analysis of variance.
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